SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject11/12/2001 3:13:23 AM
From: nigel bates  Read Replies (1) of 625
 
Genzyme General and Cambridge Antibody Technology Initiate Phase 1-2 Clinical Trial of CAT-192

CAMBRIDGE, Mass. and MELBOURN, U.K., Nov. 12 /PRNewswire/ -- Genzyme General (Nasdaq: GENZ - news) and Cambridge Antibody Technology (LSE: CAT; Nasdaq: CATG) today announced that they have initiated a Phase 1-2 clinical trial to assess the safety and efficacy of the human anti-TGF beta monoclonal antibody CAT-192 for the treatment of diffuse systemic sclerosis.
Diffuse systemic sclerosis, a form of scleroderma, is a chronic, life- threatening disorder caused by the production of excess collagen which leads to scarring of the skin and internal organs. Eighty percent of those affected by this disease are women between the ages of 25-55. About 40 percent of all patients with this disorder die within ten years of diagnosis. There is currently no effective therapy for the disease, which affects an estimated 300,000 people worldwide.
The partners have begun a randomized, double-blind, placebo-controlled trial that evaluates three different dose levels of CAT-192. Each patient will receive four infusions administered six weeks apart over the trial period. In addition to evaluating safety, the trial will study the effect of CAT-192 on several clinical and biologic markers of disease progression. A total of 36 patients will be enrolled in the trial, which will take place at seven sites in Europe, with the possible addition of other sites.
Genzyme General and Cambridge Antibody Technology have been working in partnership to develop and commercialize human TGF beta monoclonal antibodies for the treatment of diffuse systemic sclerosis since September 2000...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News